Upstream Bio Sets Phase 3 Trials for Verekitug in Severe Asthma and CRSwNP
Event summary
- Upstream Bio plans to initiate Phase 3 trials for verekitug in severe asthma and CRSwNP in Q1 2027.
- Trials will evaluate a 400 mg dose of verekitug administered every 12 weeks versus placebo.
- Each trial will enroll approximately 750 patients, with primary endpoints focused on exacerbation rates and symptom scores.
- Verekitug is the only known TSLP receptor antagonist in clinical development.
The big picture
Upstream Bio's Phase 3 plans for verekitug mark a critical step in developing a differentiated treatment for severe inflammatory respiratory diseases. The focus on a high-dose, quarterly regimen aims to address substantial unmet medical needs in both severe asthma and CRSwNP, potentially offering a convenient alternative to current therapies. The company's strategy leverages extensive Phase 2 data and FDA guidance to streamline its path to a potential 2030 launch.
What we're watching
- Clinical Efficacy
- Whether the high-dose, quarterly regimen of verekitug can deliver best-in-class efficacy in both severe asthma and CRSwNP.
- Regulatory Pathway
- The pace at which Upstream Bio can navigate FDA approvals and submit a BLA for verekitug.
- Market Differentiation
- How verekitug's unique mechanism and dosing schedule will position it against existing treatments.
Related topics